De­nali stops some work on ALS drug af­ter analy­sis showed no im­pact on key bio­mark­er

De­nali Ther­a­peu­tics’ ALS pro­gram showed no ef­fect on an im­por­tant neu­rode­gen­er­a­tion bio­mark­er that could have been used for FDA ap­proval af­ter a failed topline read­out …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER